Literature DB >> 22902347

The GENESIS project (GENeralized Early Sepsis Intervention Strategies): a multicenter quality improvement collaborative.

Chad M Cannon1, Christopher V Holthaus, Marc T Zubrow, Pat Posa, Satheesh Gunaga, Vipul Kella, Ron Elkin, Scott Davis, Bonnie Turman, Jordan Weingarten, Truman J Milling, Nathan Lidsky, Victor Coba, Arturo Suarez, James J Yang, Emanuel P Rivers.   

Abstract

BACKGROUND: Improved outcomes for severe sepsis and septic shock have been consistently observed with implementation of early best practice intervention strategies or the 6-hour resuscitation bundle (RB) in single-center studies. This multicenter study examines the in-hospital mortality effect of GENeralized Early Sepsis Intervention Strategies (GENESIS) when utilized in community and tertiary care settings.
METHODS: This study was comprised of 2 strategies to assess treatment. The first was a prospective before-and-after observational comparison of historical controls to patients receiving the RB after implementation of GENESIS in 4 community and 4 tertiary hospitals. The second was a concurrent examination comparing patients not achieving all components of the RB to those achieving all components of the RB in 1 community and 2 tertiary care hospitals after implementation of GENESIS. These 4 subgroups merged to comprise a control (historical controls treated before GENESIS and RB not achieved after GENESIS) group and treatment (patients treated after GENESIS and RB achieved after GENESIS) group for comparison.
RESULTS: The control group comprised 1554 patients not receiving the RB (952 before GENESIS and 602 RB not achieved after GENESIS). The treatment group comprised 4801 patients receiving the RB (4109 after GENESIS and 692 RB achieved after GENESIS). Patients receiving the RB (treatment group) experienced an in-hospital mortality reduction of 14% (42.8%-28.8%, P < .001) and a 5.1 day decrease in hospital length of stay (20.7 vs 15.6, P < .001) compared to those not receiving the RB (control group). Similar mortality reductions were seen in the before-and-after (43% vs 29%, P < .001) or concurrent RB not achieved versus achieved (42.5% vs 27.2%, P < .001) subgroup comparisons.
CONCLUSIONS: Patients with severe sepsis and septic shock receiving the RB in community and tertiary hospitals experience similar and significant reductions in mortality and hospital length of stay. These findings remained consistent when examined in both before-and-after and concurrent analyses. Early sepsis intervention strategies are associated with 1 life being saved for every 7 treated.

Entities:  

Keywords:  critical care; early goal-directed therapy; emergency medicine; quality improvement; resuscitation bundle; sepsis; septic shock; severe sepsis; shock

Mesh:

Year:  2012        PMID: 22902347     DOI: 10.1177/0885066612453025

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  16 in total

1.  Overview of progresses in critical care medicine 2012.

Authors:  Wei Huang; Xianyao Wan
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

2.  [Update on intensive care medicine. Most important publications from 2012-2014].

Authors:  J Knapp; M Bernhard; S Hofer; E Popp; M A Weigand
Journal:  Anaesthesist       Date:  2014-05       Impact factor: 1.041

Review 3.  Early management of sepsis with emphasis on early goal directed therapy: AME evidence series 002.

Authors:  Zhongheng Zhang; Yucai Hong; Nathan J Smischney; Han-Pin Kuo; Panagiotis Tsirigotis; Jordi Rello; Win Sen Kuan; Christian Jung; Chiara Robba; Fabio Silvio Taccone; Marc Leone; Herbert Spapen; David Grimaldi; Sven Van Poucke; Steven Q Simpson; Patrick M Honore; Stefan Hofer; Pietro Caironi
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

4.  [Essential measures for prehospital treatment of severely injured patients: The trauma care bundle].

Authors:  G Matthes; H Trentzsch; C G Wölfl; T Paffrath; S Flohe; U Schweigkofler; A Ekkernkamp; S Schulz-Drost
Journal:  Unfallchirurg       Date:  2015-08       Impact factor: 1.000

5.  Improving Outcomes in Patients With Sepsis.

Authors:  Scott B Armen; Carol V Freer; John W Showalter; Tonya Crook; Cynthia J Whitener; Cheri West; Thomas E Terndrup; Marissa Grifasi; Christopher J DeFlitch; Christopher S Hollenbeak
Journal:  Am J Med Qual       Date:  2014-09-12       Impact factor: 1.852

Review 6.  Sepsis trends: increasing incidence and decreasing mortality, or changing denominator?

Authors:  Chanu Rhee; Michael Klompas
Journal:  J Thorac Dis       Date:  2020-02       Impact factor: 2.895

7.  Compliance With the National SEP-1 Quality Measure and Association With Sepsis Outcomes: A Multicenter Retrospective Cohort Study.

Authors:  Chanu Rhee; Michael R Filbin; Anthony F Massaro; Amy L Bulger; Donna McEachern; Kathleen A Tobin; Barrett T Kitch; Bert Thurlo-Walsh; Aran Kadar; Alexandra Koffman; Anupam Pande; Yasir Hamad; David K Warren; Travis M Jones; Cara O'Brien; Deverick J Anderson; Rui Wang; Michael Klompas
Journal:  Crit Care Med       Date:  2018-10       Impact factor: 7.598

8.  Hospital staff education on severe sepsis/septic shock and hospital mortality: an original hypothesis.

Authors:  Maurizia Capuzzo; Marco Rambaldi; Giovanni Pinelli; Manuela Campesato; Antonia Pigna; Marco Zanello; Maria Barbagallo; Massimo Girardis; Elena Toschi
Journal:  BMC Anesthesiol       Date:  2012-11-20       Impact factor: 2.217

Review 9.  Effect of performance improvement programs on compliance with sepsis bundles and mortality: a systematic review and meta-analysis of observational studies.

Authors:  Elisa Damiani; Abele Donati; Giulia Serafini; Laura Rinaldi; Erica Adrario; Paolo Pelaia; Stefano Busani; Massimo Girardis
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

Review 10.  Igniting the fire: Staphylococcus aureus virulence factors in the pathogenesis of sepsis.

Authors:  Michael E Powers; Juliane Bubeck Wardenburg
Journal:  PLoS Pathog       Date:  2014-02-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.